In the preceding three months, 4 analysts have released ratings for Intellia Therapeutics (NASDAQ:NTLA), presenting a wide array of perspectives from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

	Bullish	Somewhat Bullish	Indifferent	Somewhat Bearish	Bearish
Total Ratings	4	0	0	0	0
Last 30D	1	0	0	0	0
1M Ago	2	0	0	0	0
2M Ago	1	0	0	0	0
3M Ago	0	0	0	0	0

The 12-month price targets, analyzed by analysts, offer insights with an average target of $27.0, a high estimate of $30.00, and a low estimate of $25.00. Surpassing the previous average price target of $23.00, the current average has increased by 17.39%.

Deciphering Analyst Ratings: An In-Depth Analysis

An in-depth analysis of recent analyst actions unveils how financial experts perceive Intellia Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
Mitchell S. Kapoor	HC Wainwright & Co.	Raises	Buy	$30.00	$25.00
Geulah Livshits	Chardan Capital	Raises	Buy	$27.00	$26.00
Geulah Livshits	Chardan Capital	Maintains	Buy	$26.00	$26.00
Mitchell S. Kapoor	HC Wainwright & Co.	Raises	Buy	$25.00	$15.00

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Intellia Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intellia Therapeutics compared to the broader market.
• Price Targets: Understanding forecasts, analysts offer estimates for Intellia Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

Capture valuable insights into Intellia Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on Intellia Therapeutics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

About Intellia Therapeutics

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Financial Milestones: Intellia Therapeutics's Journey

Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Growth: Intellia Therapeutics's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of 51.27%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -735.19%, the company may need to address challenges in effective cost control.

Return on Equity (ROE): Intellia Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -13.85%, the company may face hurdles in achieving optimal financial performance.

Return on Assets (ROA): Intellia Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -11.11%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: Intellia Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.13, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

What Are Analyst Ratings?

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.